The interaction mechanism of mental disorders and diabetes and the current status of intervention_West China Medical Journal

Authors：

 WANG Hongming

President & Dean’s Office, the Fourth People’s Hospital of Chengdu, Chengdu, Sichuan 610036, P. R. China;

Corresponding author：

WANG Hongming, Email: wanghongming2021@163.com

Keywords：

Mental disorders; Diabetes; Interaction; Interventions

DOI：

10.7507/1002-0179.202106210

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The interaction mechanism between mental disorders and diabetes is complex, involving genetics, endocrine metabolism, inflammation, oxidative stress and other aspects, which makes it difficult to treat patients with mental disorders complicated by diabetes. Such patients mostly use drugs and non-drug interventions to relieve symptoms of mental disorders and improve blood sugar levels, but the mechanism of mental disorders and diabetes needs to be systematically summarized and needs practical means to intervene. This article starts with the pathogenesis of diabetes and then describes the interaction mechanism of schizophrenia, bipolar disorder, depression and diabetes in detail. Finally, the intervention measures for patients with mental disorders complicated by diabetes are summarized, which aims to provide a reference for medical staff engaged in related work.

Citation： WANG Hongming. The interaction mechanism of mental disorders and diabetes and the current status of intervention. West China Medical Journal, 2021, 36(7): 846-853. doi: 10.7507/1002-0179.202106210 Copy

1.	Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
2.	孙洪敏. 精神障碍伴发糖尿病患者的护理措施研究及分析. 糖尿病新世界, 2018, 21(11): 167-168.
3.	张丹. 健康教育在糖尿病伴发精神障碍患者中的应用效果. 中国医药指南, 2020, 18(36): 210-211.
4.	Diabetes Canada Clinical Practice Guidelines Expert Committee, Robinson DJ, Coons M, et al. Diabetes and Mental Health. Can J Diabetes, 2018, 42(Suppl 1): S130-S141.
5.	American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
6.	Chellappan DK, Sivam NS, Teoh KX, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother, 2018, 108: 1188-1200.
7.	Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes, 2018, 19(3): 346-353.
8.	Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr, 2019, 13(1): 364-372.
9.	Bakay M, Pandey R, Grant SFA, et al. The genetic contribution to type 1 diabetes. Curr Diab Rep, 2019, 19(11): 116.
10.	Principi N, Berioli MG, Bianchini S, et al. Type 1 diabetes and viral infections: what is the relationship?. J Clin Virol, 2017, 96: 26-31.
11.	Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet, 2016, 387(10035): 2340-2348.
12.	Dedrick S, Sundaresh B, Huang Q, et al. The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis. Front Endocrinol (Lausanne), 2020, 11: 78.
13.	Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 2014, 383(9922): 1068-1083.
14.	Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med, 2014, 371(23): 2237-2238.
15.	Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
16.	Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science, 2016, 354(6308): 69-73.
17.	孟建凤, 姜诚勇, 凌迎春, 等. 精神分裂症合并糖尿病医院感染及护理干预对策分析. 中华医院感染学杂志, 2018, 28(9): 1417-1419.
18.	刘启龙, 王妮娜. 精神分裂症患者服用抗精神病药导致糖尿病的临床分析. 河北医药, 2019, 41(20): 3141-3144.
19.	王会秋, 李群, 徐桂娟, 等. 首发精神分裂症患者康复治疗现状. 中国健康心理学杂志, 2018, 26(11): 1756-1761.
20.	魏亮. 糖尿病并发症治疗药物的研究进展. 中国城乡企业卫生, 2021, 36(4): 40-42.
21.	于婷. 慢性精神分裂症合并糖尿病患者的认知功能研究. 山东: 青岛大学, 2017: 16-44.
22.	薛莹, 赵青枫, 林绍陈, 等. 精神分裂症与糖尿病关系的研究进展. 临床医药文献电子杂志, 2017, 4(67): 13254-13256.
23.	Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One, 2016, 11(11): e0166429.
24.	Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand, 2015, 132(2): 144-157.
25.	Coclami T, Cross M. Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus. East Mediterr Health J, 2011, 17(10): 777-783.
26.	汪晓晖, 郭向晴, 鲍晨曦, 等. 精神分裂症患者 5-羟色胺 2C 受体基因多态性与 2 型糖尿病共病的关联研究. 临床精神医学杂志, 2017, 27(3): 153-156.
27.	Mamakou V, Hackinger S, Zengini E, et al. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. BMC Psychiatry, 2018, 18(1): 249.
28.	郭向晴, 赵静, 易正辉, 等. 精神分裂症并发 2 型糖尿病与五羟色胺 2C 受体基因多态性的关联性. 复旦学报(医学版), 2021, 48(1): 1-7.
29.	张昌, 冯志强, 杨宏亮, 等. 长期住院女性精神分裂症患者 2 型糖尿病发生率及相关因素研究. 中国实用医药, 2018, 13(28): 32-34.
30.	Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry, 2016, 50(5): 488-494.
31.	Postolache TT, Del Bosque-Plata L, Jabbour S, et al. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet, 2019, 180(3): 186-203.
32.	王嘉欣. 中国汉族人群精神分裂症和 2 型糖尿病共享易感基因及其致病机制研究. 长春: 吉林大学, 2015: 28-38.
33.	Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol, 2021, 24(5): 367-382.
34.	Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res, 2010, 123(2/3): 234-243.
35.	Lovestone S, Killick R, Di Forti M, et al. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci, 2007, 30(4): 142-149.
36.	Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry, 2019, 76(10): 1052-1062.
37.	梅希, 吴锦林. 抗精神病药物诱导糖尿病的分子机制研究进展. 中国糖尿病杂志, 2018, 26(7): 608-612.
38.	隋国梁, 万易, 刘佳. 探讨利培酮对精神分裂症合并糖尿病患者的疗效及认知功能的影响. 中国卫生标准管理, 2017, 8(8): 75-76.
39.	徐劲节, Qi Dake, 崔东红. 奥氮平致代谢紊乱和心血管疾病研究进展. 中国神经精神疾病杂志, 2016, 42(5): 303-306.
40.	余海玲, 徐英妹, 杨兰. 精神分裂症并发糖尿病相关因素分析. 医学理论与实践, 2019, 32(16): 2554-2556.
41.	蔡骅琳, 江沛, 李焕德, 等. 下丘脑-垂体-肾上腺轴与精神分裂症的关系. 中国神经精神疾病杂志, 2013, 39(11): 688-691.
42.	蒋昕, 纪家武, 陈红岩, 等. 精神分裂症下丘脑-垂体-肾上腺轴功能研究. 临床精神医学杂志, 2008(5): 292-294.
43.	刘莉. 精神分裂症合并糖尿病的护理体会. 糖尿病新世界, 2019, 22(5): 166-167.
44.	Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry, 2015, 2(5): 431-451.
45.	Miller JN, Black D. Bipolar disorder and suicide: a review. Curr Psychiatry Rep, 2020, 22(2): 6.
46.	Teixeira AL, Colpo GD, Fries GR, et al. Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother, 2019, 19(1): 67-81.
47.	Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris, 2013, 107(4): 278-285.
48.	Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the AESOP first-episode cohort. Schizophr Bull, 2015, 41(3): 664-673.
49.	Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol, 2021, 18(2): 136-145.
50.	Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med, 2019, 51(5/6): 281-293.
51.	Chien IC, Chang KC, Lin CH, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry, 2010, 32(6): 577-582.
52.	Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord, 2016, 4(1): 13.
53.	Choat HM, Martin A, Mick GJ, et al. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: trial design and methodology. Contemp Clin Trials, 2019, 82: 93-100.
54.	Grain R, Lally J, Stubbs B, et al. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: a systematic review, meta-analysis, and case series. Psychiatry Clin Neurosci, 2017, 71(10): 678-689.
55.	Steardo L Jr, de Filippis R, Carbone EA, et al. Sleep disturbance in bipolar disorder: neuroglia and circadian rhythms. Front Psychiatry, 2019, 10: 501.
56.	潘雨, 孙少俐. 睡眠障碍与老年 2 型糖尿病关系的研究进展. 中西医结合心血管病电子杂志, 2019, 7(3): 18-19.
57.	唐倩. 中老年人夜间睡眠时间与 2 型糖尿病及胰岛素抵抗的关系及其机制探讨. 重庆: 重庆医科大学, 2015: 12-18.
58.	Hajek T, McIntyre R, Alda M. Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry, 2016, 29(1): 1-6.
59.	Tannous J, Cao B, Stanley JA, et al. Altered neurochemistry in the anterior white matter of bipolar children and adolescents: a multivoxel ¹H MRS study. Mol Psychiatry, 2020: 10.
60.	Zhao X, Han Q, Gang X, et al. Altered brain metabolites in patients with diabetes mellitus and related complications-evidence from ¹H MRS study. Biosci Rep, 2018, 38(5): BSR20180660.
61.	Hajek T, Calkin C, Blagdon R, et al. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry, 2015, 77(3): 295-303.
62.	Nandi A, Yan LJ, Jana CK, et al. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cell Longev, 2019, 2019: 9613090.
63.	Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, et al. Oxidative stress parameters and antioxidants in patients with bipolar disorder: results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord, 2021, 23(2): 117-129.
64.	Bhattamisra SK, Siang TC, Rong CY, et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update. Curr Diabetes Rev, 2019, 15(5): 382-394.
65.	Yehuda R. Stress and glucocorticoid. Science, 1997, 275(5306): 1662-1663.
66.	Fitzgerald PJ. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton Autacoid Pharmacol, 2009, 29(4): 143-156.
67.	Lambert CG, Mazurie AJ, Lauve NR, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord, 2016, 18(3): 247-260.
68.	Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in japanese and american subjects. Nutrients, 2018, 10(8): 1011.
69.	Lin JR, Huang SH, Wu CH, et al. Valproic acid suppresses autoimmune recurrence and allograft rejection in islet transplantation through induction of the differentiation of regulatory t cells and can be used in cell therapy for type1 diabetes. Pharmaceuticals (Basel), 2021, 14(5): 475.
70.	Khan S, Jena G. Valproic acid improves glucose homeostasis by increasing beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J Biochem Mol Toxicol, 2016, 30(9): 438-446.
71.	王忠, 罗诚, 张跃坤, 等. 服用非经典抗精神病药与双相情感障碍患者代谢综合征发生相关性分析. 心理月刊, 2020, 15(2): 70.
72.	Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 2020, 7(1): 64-77.
73.	Holt RIG. association between antipsychotic medication use and diabetes. Curr Diab Rep, 2019, 19(10): 96.
74.	Ohta Y, Kosaka Y, Kishimoto N, et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes, 2011, 60(12): 3208-3216.
75.	Nestsiarovich A, Kerner B, Mazurie AJ, et al. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology, 2020, 112: 104511.
76.	Kalra G, Gill S, Tang TS. Depression and diabetes distress in south asian adults living in low- and middle-income countries: a scoping review. Can J Diabetes, 2020, 44(6): 521-529.
77.	World Health Organization. Depression and other common mental disorders. (2017-01-03)[2021-6-22]. https://www.who.int/publications/i/item/depression-global-health-estimates.
78.	沈宛颖, 曾昱兴, 李文豪, 等. 基于 GBD 大数据的中国抑郁负担现状和趋势分析. 职业与健康, 2021, 37(8): 1087-1092.
79.	Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol, 2019, 56(6): 631-650.
80.	Wang F, Wang S, Zong QQ, et al. Prevalence of comorbid major depressive disorder in type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med, 2019, 36(8): 961-969.
81.	Alzoubi A, Abunaser R, Khassawneh A, et al. The bidirectional relationship between diabetes and depression: a literature review. Korean J Fam Med, 2018, 39(3): 137-146.
82.	Semenkovich K, Brown ME, Svrakic DM, et al. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs, 2015, 75(6): 577-587.
83.	Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun, 2020, 11(1): 5881.
84.	Pomytkin IA, Cline BH, Anthony DC, et al. Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: a reciprocal risk factor for depression and insulin resistance?. Behav Brain Res, 2015, 276: 111-117.
85.	Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol, 2016, 12(3): 133-143.
86.	何文丽, 陈巧珍. 内源性大麻素系统在抑郁障碍诊治中的研究进展. 精神医学杂志, 2021, 34(1): 79-83.
87.	Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev, 2014, 45: 46-62.
88.	阳璐, 陈俊, 方贻儒. 氧化应激指标在抑郁症中的研究进展. 临床精神医学杂志, 2020, 30(3): 208-210.
89.	Yamada C, Kishimoto N, Urata N, et al. Relationship between serum antioxidative vitamin concentrations and type 2 diabetes in Japanese subjects. J Nutr Sci Vitaminol (Tokyo), 2020, 66(4): 289-295.
90.	Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun, 2018, 69: 28-34.
91.	Yu Z, Lin L, Jiang Y, et al. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol Neurobiol, 2019, 56(4): 2314-2327.
92.	Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology, 2017, 42(1): 193-215.
93.	Karabatsiakis A, Böck C, Salinas-Manrique J, et al. Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry, 2014, 4(6): e397.
94.	Yuzefovych LV, Pastukh VM, Ruchko MV, et al. Plasma mitochondrial DNA is elevated in obese type 2 diabetes mellitus patients and correlates positively with insulin resistance. PLoS One, 2019, 14(10): e0222278.
95.	Wang YL, Koh WP, Yuan JM, et al. Plasma ferritin, C-reactive protein, and risk of incident type 2 diabetes in Singapore Chinese men and women. Diabetes Res Clin Pract, 2017, 128: 109-118.
96.	Passaro A, Vigna GB, Romani A, et al. Distribution of paraoxonase-1 (PON-1) and lipoprotein phospholipase A2 (Lp-PLA2) across lipoprotein subclasses in subjects with type 2 diabetes. Oxid Med Cell Longev, 2018, 2018: 1752940.
97.	Wu D, Wu C, Zhong Y. The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J Cell Mol Med, 2018, 22(9): 4283-4291.
98.	苑杰, 严辞, 李永秋, 等. 抗抑郁药物长期治疗的潜在风险性. 中国新药与临床杂志, 2016, 35(7): 464-468.
99.	汤智慧, 朱曼, 郭代红. 1 例 2 型糖尿病患者使用抗抑郁药物的药学监护. 中国药业, 2015, 24(10): 75-76.
100.	魏嘉欣. 利培酮联合二甲双胍治疗精神分裂症合并 2 型糖尿病患者的效果观察. 实用糖尿病杂志, 2021, 17(1): 158-159.
101.	朱杰, 皇甫宇欢. 老年 2 型糖尿病伴发精神障碍抗精神病的临床探讨. 人人健康, 2018(12): 8.
102.	姜玉涛, 关勇. 阿立哌唑与富马酸喹硫平联用治疗精神分裂症的效果分析. 河北医药, 2019, 41(11): 1716-1718.
103.	何金珠. 齐拉西酮治疗早期精神分裂症伴糖尿病的研究. 中国卫生标准管理, 2020, 11(13): 67-68.
104.	陈孔树, 吴祖美. 黄芪辅助治疗伴糖尿病的精神分裂症患者对血糖水平影响. 中外医疗, 2019, 38(35): 184-186.
105.	曹媛媛, 高淑英, 石川, 等. 疏肝益肾汤加减电针疗法治疗慢性精神分裂症共病 2 型糖尿病认知功能障碍的疗效观察. 中国药物与临床, 2021, 21(6): 972-974.
106.	周琦. 针对性护理对精神分裂症伴糖尿病患者血糖控制效果的影响. 当代护士(上旬刊), 2021, 28(5): 92-93.
107.	刘向群, 朱明文, 赵志君, 等. 精神分裂症合并糖尿病患者膳食干预效果及其影响因素. 山东医药, 2019, 59(8): 69-72.
108.	宋珈莹, 孙赫, 王会娟, 等. 运动疗法对精神分裂症合并糖尿病患者体重及血糖的影响. 中国当代医药, 2020, 27(16): 81-84.
109.	高淑英, 曹媛媛. 精神分裂症合并 2 型糖尿病及伴发认知功能障碍患者中医疗法干预. 山西医药杂志, 2020, 49(14): 1790-1792.
110.	胡耀华, 林明钦, 邹敏, 等. 叙事疗法结合 PDCA 循环管理在精神分裂症伴糖尿病患者中的应用. 中外医学研究, 2020, 18(17): 168-170.
111.	甘建伟. 精神分裂症合并糖尿病的护理干预效果及相关指标分析. 糖尿病新世界, 2021, 24(3): 109-111.
112.	McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res, 2006, 86(1/3): 36-44.
113.	Wong J, Mehta G. Efficacy of depression management in an integrated psychiatric-diabetes education clinic for comorbid depression and diabetes mellitus types 1 and 2. Can J Diabetes, 2020, 44(6): 455-460.
114.	国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南(第 2 版). 中国医学前沿杂志(电子版), 2019, 11(7): 1-78.
115.	陈晓燕. 帕罗西汀对 62 例抑郁症合并 2 型糖尿病患者的临床治疗观察探讨. 糖尿病新世界, 2019, 22(24): 58-60.
116.	党亚楠, 张伟, 惠晶, 等. 当代老龄化社会糖尿病伴焦虑、抑郁的现状及应对措施. 中国社区医师, 2018, 34(22): 9-10.
117.	Schnitzer K, Cather C, Thorndike AN, et al. Improved glycemic control in adults with serious mental illness and diabetes with a behavioral and educational intervention. Psychiatr Serv, 2020, 71(7): 730-733.
118.	林明芳. 临床护理干预对老年精神障碍合并糖尿病患者生活质量的影响评价. 糖尿病新世界, 2020, 23(12): 166-168.
119.	Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry, 2016, 15(2): 166-174.
120.	朱大龙, 陆菊明. 《中国 2 型糖尿病防治指南(2020 年版)》编写说明. 中华糖尿病杂志, 2021, 13(4): 312-314.
121.	中华医学会精神医学分会精神分裂症协作组. 精神分裂症患者代谢综合征管理的中国专家共识. 中华精神科杂志, 2020, 53(1): 3-10.
122.	刘江洋, 缪海燕. 社区严重精神障碍患者共患糖尿病的调查及分析. 交通医学, 2019, 33(3): 296-297.
123.	刘虎军, 朱艺欣, 李海涛. 抗精神病药导致糖尿病的相关危险因素 Logistic 回归分析. 河北医药, 2020, 42(22): 3497-3499.

1. Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
2. 孙洪敏. 精神障碍伴发糖尿病患者的护理措施研究及分析. 糖尿病新世界, 2018, 21(11): 167-168.
3. 张丹. 健康教育在糖尿病伴发精神障碍患者中的应用效果. 中国医药指南, 2020, 18(36): 210-211.
4. Diabetes Canada Clinical Practice Guidelines Expert Committee, Robinson DJ, Coons M, et al. Diabetes and Mental Health. Can J Diabetes, 2018, 42(Suppl 1): S130-S141.
5. American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
6. Chellappan DK, Sivam NS, Teoh KX, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother, 2018, 108: 1188-1200.
7. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes, 2018, 19(3): 346-353.
8. Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr, 2019, 13(1): 364-372.
9. Bakay M, Pandey R, Grant SFA, et al. The genetic contribution to type 1 diabetes. Curr Diab Rep, 2019, 19(11): 116.
10. Principi N, Berioli MG, Bianchini S, et al. Type 1 diabetes and viral infections: what is the relationship?. J Clin Virol, 2017, 96: 26-31.
11. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet, 2016, 387(10035): 2340-2348.
12. Dedrick S, Sundaresh B, Huang Q, et al. The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis. Front Endocrinol (Lausanne), 2020, 11: 78.
13. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 2014, 383(9922): 1068-1083.
14. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med, 2014, 371(23): 2237-2238.
15. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
16. Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science, 2016, 354(6308): 69-73.
17. 孟建凤, 姜诚勇, 凌迎春, 等. 精神分裂症合并糖尿病医院感染及护理干预对策分析. 中华医院感染学杂志, 2018, 28(9): 1417-1419.
18. 刘启龙, 王妮娜. 精神分裂症患者服用抗精神病药导致糖尿病的临床分析. 河北医药, 2019, 41(20): 3141-3144.
19. 王会秋, 李群, 徐桂娟, 等. 首发精神分裂症患者康复治疗现状. 中国健康心理学杂志, 2018, 26(11): 1756-1761.
20. 魏亮. 糖尿病并发症治疗药物的研究进展. 中国城乡企业卫生, 2021, 36(4): 40-42.
21. 于婷. 慢性精神分裂症合并糖尿病患者的认知功能研究. 山东: 青岛大学, 2017: 16-44.
22. 薛莹, 赵青枫, 林绍陈, 等. 精神分裂症与糖尿病关系的研究进展. 临床医药文献电子杂志, 2017, 4(67): 13254-13256.
23. Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One, 2016, 11(11): e0166429.
24. Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand, 2015, 132(2): 144-157.
25. Coclami T, Cross M. Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus. East Mediterr Health J, 2011, 17(10): 777-783.
26. 汪晓晖, 郭向晴, 鲍晨曦, 等. 精神分裂症患者 5-羟色胺 2C 受体基因多态性与 2 型糖尿病共病的关联研究. 临床精神医学杂志, 2017, 27(3): 153-156.
27. Mamakou V, Hackinger S, Zengini E, et al. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. BMC Psychiatry, 2018, 18(1): 249.
28. 郭向晴, 赵静, 易正辉, 等. 精神分裂症并发 2 型糖尿病与五羟色胺 2C 受体基因多态性的关联性. 复旦学报(医学版), 2021, 48(1): 1-7.
29. 张昌, 冯志强, 杨宏亮, 等. 长期住院女性精神分裂症患者 2 型糖尿病发生率及相关因素研究. 中国实用医药, 2018, 13(28): 32-34.
30. Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry, 2016, 50(5): 488-494.
31. Postolache TT, Del Bosque-Plata L, Jabbour S, et al. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet, 2019, 180(3): 186-203.
32. 王嘉欣. 中国汉族人群精神分裂症和 2 型糖尿病共享易感基因及其致病机制研究. 长春: 吉林大学, 2015: 28-38.
33. Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol, 2021, 24(5): 367-382.
34. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res, 2010, 123(2/3): 234-243.
35. Lovestone S, Killick R, Di Forti M, et al. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci, 2007, 30(4): 142-149.
36. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry, 2019, 76(10): 1052-1062.
37. 梅希, 吴锦林. 抗精神病药物诱导糖尿病的分子机制研究进展. 中国糖尿病杂志, 2018, 26(7): 608-612.
38. 隋国梁, 万易, 刘佳. 探讨利培酮对精神分裂症合并糖尿病患者的疗效及认知功能的影响. 中国卫生标准管理, 2017, 8(8): 75-76.
39. 徐劲节, Qi Dake, 崔东红. 奥氮平致代谢紊乱和心血管疾病研究进展. 中国神经精神疾病杂志, 2016, 42(5): 303-306.
40. 余海玲, 徐英妹, 杨兰. 精神分裂症并发糖尿病相关因素分析. 医学理论与实践, 2019, 32(16): 2554-2556.
41. 蔡骅琳, 江沛, 李焕德, 等. 下丘脑-垂体-肾上腺轴与精神分裂症的关系. 中国神经精神疾病杂志, 2013, 39(11): 688-691.
42. 蒋昕, 纪家武, 陈红岩, 等. 精神分裂症下丘脑-垂体-肾上腺轴功能研究. 临床精神医学杂志, 2008(5): 292-294.
43. 刘莉. 精神分裂症合并糖尿病的护理体会. 糖尿病新世界, 2019, 22(5): 166-167.
44. Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry, 2015, 2(5): 431-451.
45. Miller JN, Black D. Bipolar disorder and suicide: a review. Curr Psychiatry Rep, 2020, 22(2): 6.
46. Teixeira AL, Colpo GD, Fries GR, et al. Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother, 2019, 19(1): 67-81.
47. Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris, 2013, 107(4): 278-285.
48. Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the AESOP first-episode cohort. Schizophr Bull, 2015, 41(3): 664-673.
49. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol, 2021, 18(2): 136-145.
50. Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med, 2019, 51(5/6): 281-293.
51. Chien IC, Chang KC, Lin CH, et al. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry, 2010, 32(6): 577-582.
52. Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord, 2016, 4(1): 13.
53. Choat HM, Martin A, Mick GJ, et al. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: trial design and methodology. Contemp Clin Trials, 2019, 82: 93-100.
54. Grain R, Lally J, Stubbs B, et al. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: a systematic review, meta-analysis, and case series. Psychiatry Clin Neurosci, 2017, 71(10): 678-689.
55. Steardo L Jr, de Filippis R, Carbone EA, et al. Sleep disturbance in bipolar disorder: neuroglia and circadian rhythms. Front Psychiatry, 2019, 10: 501.
56. 潘雨, 孙少俐. 睡眠障碍与老年 2 型糖尿病关系的研究进展. 中西医结合心血管病电子杂志, 2019, 7(3): 18-19.
57. 唐倩. 中老年人夜间睡眠时间与 2 型糖尿病及胰岛素抵抗的关系及其机制探讨. 重庆: 重庆医科大学, 2015: 12-18.
58. Hajek T, McIntyre R, Alda M. Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry, 2016, 29(1): 1-6.
59. Tannous J, Cao B, Stanley JA, et al. Altered neurochemistry in the anterior white matter of bipolar children and adolescents: a multivoxel ¹H MRS study. Mol Psychiatry, 2020: 10.
60. Zhao X, Han Q, Gang X, et al. Altered brain metabolites in patients with diabetes mellitus and related complications-evidence from ¹H MRS study. Biosci Rep, 2018, 38(5): BSR20180660.
61. Hajek T, Calkin C, Blagdon R, et al. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry, 2015, 77(3): 295-303.
62. Nandi A, Yan LJ, Jana CK, et al. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cell Longev, 2019, 2019: 9613090.
63. Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, et al. Oxidative stress parameters and antioxidants in patients with bipolar disorder: results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord, 2021, 23(2): 117-129.
64. Bhattamisra SK, Siang TC, Rong CY, et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update. Curr Diabetes Rev, 2019, 15(5): 382-394.
65. Yehuda R. Stress and glucocorticoid. Science, 1997, 275(5306): 1662-1663.
66. Fitzgerald PJ. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton Autacoid Pharmacol, 2009, 29(4): 143-156.
67. Lambert CG, Mazurie AJ, Lauve NR, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord, 2016, 18(3): 247-260.
68. Kuwabara M, Kuwabara R, Niwa K, et al. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in japanese and american subjects. Nutrients, 2018, 10(8): 1011.
69. Lin JR, Huang SH, Wu CH, et al. Valproic acid suppresses autoimmune recurrence and allograft rejection in islet transplantation through induction of the differentiation of regulatory t cells and can be used in cell therapy for type1 diabetes. Pharmaceuticals (Basel), 2021, 14(5): 475.
70. Khan S, Jena G. Valproic acid improves glucose homeostasis by increasing beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J Biochem Mol Toxicol, 2016, 30(9): 438-446.
71. 王忠, 罗诚, 张跃坤, 等. 服用非经典抗精神病药与双相情感障碍患者代谢综合征发生相关性分析. 心理月刊, 2020, 15(2): 70.
72. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 2020, 7(1): 64-77.
73. Holt RIG. association between antipsychotic medication use and diabetes. Curr Diab Rep, 2019, 19(10): 96.
74. Ohta Y, Kosaka Y, Kishimoto N, et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes, 2011, 60(12): 3208-3216.
75. Nestsiarovich A, Kerner B, Mazurie AJ, et al. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology, 2020, 112: 104511.
76. Kalra G, Gill S, Tang TS. Depression and diabetes distress in south asian adults living in low- and middle-income countries: a scoping review. Can J Diabetes, 2020, 44(6): 521-529.
77. World Health Organization. Depression and other common mental disorders. (2017-01-03)[2021-6-22]. https://www.who.int/publications/i/item/depression-global-health-estimates.
78. 沈宛颖, 曾昱兴, 李文豪, 等. 基于 GBD 大数据的中国抑郁负担现状和趋势分析. 职业与健康, 2021, 37(8): 1087-1092.
79. Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol, 2019, 56(6): 631-650.
80. Wang F, Wang S, Zong QQ, et al. Prevalence of comorbid major depressive disorder in type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med, 2019, 36(8): 961-969.
81. Alzoubi A, Abunaser R, Khassawneh A, et al. The bidirectional relationship between diabetes and depression: a literature review. Korean J Fam Med, 2018, 39(3): 137-146.
82. Semenkovich K, Brown ME, Svrakic DM, et al. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs, 2015, 75(6): 577-587.
83. Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun, 2020, 11(1): 5881.
84. Pomytkin IA, Cline BH, Anthony DC, et al. Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: a reciprocal risk factor for depression and insulin resistance?. Behav Brain Res, 2015, 276: 111-117.
85. Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol, 2016, 12(3): 133-143.
86. 何文丽, 陈巧珍. 内源性大麻素系统在抑郁障碍诊治中的研究进展. 精神医学杂志, 2021, 34(1): 79-83.
87. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev, 2014, 45: 46-62.
88. 阳璐, 陈俊, 方贻儒. 氧化应激指标在抑郁症中的研究进展. 临床精神医学杂志, 2020, 30(3): 208-210.
89. Yamada C, Kishimoto N, Urata N, et al. Relationship between serum antioxidative vitamin concentrations and type 2 diabetes in Japanese subjects. J Nutr Sci Vitaminol (Tokyo), 2020, 66(4): 289-295.
90. Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun, 2018, 69: 28-34.
91. Yu Z, Lin L, Jiang Y, et al. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol Neurobiol, 2019, 56(4): 2314-2327.
92. Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology, 2017, 42(1): 193-215.
93. Karabatsiakis A, Böck C, Salinas-Manrique J, et al. Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. Transl Psychiatry, 2014, 4(6): e397.
94. Yuzefovych LV, Pastukh VM, Ruchko MV, et al. Plasma mitochondrial DNA is elevated in obese type 2 diabetes mellitus patients and correlates positively with insulin resistance. PLoS One, 2019, 14(10): e0222278.
95. Wang YL, Koh WP, Yuan JM, et al. Plasma ferritin, C-reactive protein, and risk of incident type 2 diabetes in Singapore Chinese men and women. Diabetes Res Clin Pract, 2017, 128: 109-118.
96. Passaro A, Vigna GB, Romani A, et al. Distribution of paraoxonase-1 (PON-1) and lipoprotein phospholipase A2 (Lp-PLA2) across lipoprotein subclasses in subjects with type 2 diabetes. Oxid Med Cell Longev, 2018, 2018: 1752940.
97. Wu D, Wu C, Zhong Y. The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J Cell Mol Med, 2018, 22(9): 4283-4291.
98. 苑杰, 严辞, 李永秋, 等. 抗抑郁药物长期治疗的潜在风险性. 中国新药与临床杂志, 2016, 35(7): 464-468.
99. 汤智慧, 朱曼, 郭代红. 1 例 2 型糖尿病患者使用抗抑郁药物的药学监护. 中国药业, 2015, 24(10): 75-76.
100. 魏嘉欣. 利培酮联合二甲双胍治疗精神分裂症合并 2 型糖尿病患者的效果观察. 实用糖尿病杂志, 2021, 17(1): 158-159.
101. 朱杰, 皇甫宇欢. 老年 2 型糖尿病伴发精神障碍抗精神病的临床探讨. 人人健康, 2018(12): 8.
102. 姜玉涛, 关勇. 阿立哌唑与富马酸喹硫平联用治疗精神分裂症的效果分析. 河北医药, 2019, 41(11): 1716-1718.
103. 何金珠. 齐拉西酮治疗早期精神分裂症伴糖尿病的研究. 中国卫生标准管理, 2020, 11(13): 67-68.
104. 陈孔树, 吴祖美. 黄芪辅助治疗伴糖尿病的精神分裂症患者对血糖水平影响. 中外医疗, 2019, 38(35): 184-186.
105. 曹媛媛, 高淑英, 石川, 等. 疏肝益肾汤加减电针疗法治疗慢性精神分裂症共病 2 型糖尿病认知功能障碍的疗效观察. 中国药物与临床, 2021, 21(6): 972-974.
106. 周琦. 针对性护理对精神分裂症伴糖尿病患者血糖控制效果的影响. 当代护士(上旬刊), 2021, 28(5): 92-93.
107. 刘向群, 朱明文, 赵志君, 等. 精神分裂症合并糖尿病患者膳食干预效果及其影响因素. 山东医药, 2019, 59(8): 69-72.
108. 宋珈莹, 孙赫, 王会娟, 等. 运动疗法对精神分裂症合并糖尿病患者体重及血糖的影响. 中国当代医药, 2020, 27(16): 81-84.
109. 高淑英, 曹媛媛. 精神分裂症合并 2 型糖尿病及伴发认知功能障碍患者中医疗法干预. 山西医药杂志, 2020, 49(14): 1790-1792.
110. 胡耀华, 林明钦, 邹敏, 等. 叙事疗法结合 PDCA 循环管理在精神分裂症伴糖尿病患者中的应用. 中外医学研究, 2020, 18(17): 168-170.
111. 甘建伟. 精神分裂症合并糖尿病的护理干预效果及相关指标分析. 糖尿病新世界, 2021, 24(3): 109-111.
112. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res, 2006, 86(1/3): 36-44.
113. Wong J, Mehta G. Efficacy of depression management in an integrated psychiatric-diabetes education clinic for comorbid depression and diabetes mellitus types 1 and 2. Can J Diabetes, 2020, 44(6): 455-460.
114. 国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南(第 2 版). 中国医学前沿杂志(电子版), 2019, 11(7): 1-78.
115. 陈晓燕. 帕罗西汀对 62 例抑郁症合并 2 型糖尿病患者的临床治疗观察探讨. 糖尿病新世界, 2019, 22(24): 58-60.
116. 党亚楠, 张伟, 惠晶, 等. 当代老龄化社会糖尿病伴焦虑、抑郁的现状及应对措施. 中国社区医师, 2018, 34(22): 9-10.
117. Schnitzer K, Cather C, Thorndike AN, et al. Improved glycemic control in adults with serious mental illness and diabetes with a behavioral and educational intervention. Psychiatr Serv, 2020, 71(7): 730-733.
118. 林明芳. 临床护理干预对老年精神障碍合并糖尿病患者生活质量的影响评价. 糖尿病新世界, 2020, 23(12): 166-168.
119. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry, 2016, 15(2): 166-174.
120. 朱大龙, 陆菊明. 《中国 2 型糖尿病防治指南(2020 年版)》编写说明. 中华糖尿病杂志, 2021, 13(4): 312-314.
121. 中华医学会精神医学分会精神分裂症协作组. 精神分裂症患者代谢综合征管理的中国专家共识. 中华精神科杂志, 2020, 53(1): 3-10.
122. 刘江洋, 缪海燕. 社区严重精神障碍患者共患糖尿病的调查及分析. 交通医学, 2019, 33(3): 296-297.
123. 刘虎军, 朱艺欣, 李海涛. 抗精神病药导致糖尿病的相关危险因素 Logistic 回归分析. 河北医药, 2020, 42(22): 3497-3499.

West China Medical Journal

The interaction mechanism of mental disorders and diabetes and the current status of intervention

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content